Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about trying PTD-DBM for hair loss treatment. Users are curious about its effectiveness and results.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

Breezula (clascoterone) Phase 3 hair loss trial results are delayed, with no official updates yet. The acne version is approved, but hair loss results are still pending.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

The conversation discusses whether 2.5mg of dutasteride or 200mg of testosterone weekly is more influential in preventing hair loss, with various personal experiences indicating that the effectiveness is dependent on the individual's genetic profile. Some users report that dutasteride is likely to be more effective at the given doses.

The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.

People are discussing using tretinoin gel with minoxidil to improve hair growth, especially for those who didn't respond to minoxidil alone. They apply a mix of tretinoin gel and minoxidil to the scalp, which is said to be more effective than minoxidil by itself.

The user switched from Pyrilutamide to RU58841, changed their Minoxidil solution, and continued using low-dose Finasteride, derma rolling, and specific shampoo. They asked others about their plans after Pyrilutamide's disappointing results.

CB 03 01 (Breezula) was tried for hair loss but showed no significant improvement, with issues in dissolving and application. Finasteride and dutasteride remain the most effective treatments, while minoxidil is also used; CB's effectiveness is questioned, and topical alternatives like bicalutamide are considered.

A potential new treatment for hair loss, Pyrilutamide, and the discussion of whether or not people should still be taking traditional treatments like Minoxidil and Finasteride with it.

Hair loss treatments like spironolactone often require lifelong use to maintain results. Stopping the medication can lead to increased testosterone levels and potential hair loss.

Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.

The user experienced significant hair regrowth using oral minoxidil, finasteride, and topical dutasteride, with no side effects. They plan to continue these treatments long-term to maintain results.

PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.

A woman experiencing hormonal hair loss is on dutasteride and bicalutamide, which initially improved her hair, but she is now experiencing a second shedding phase with significant short hair loss. Despite normal hormone levels and no deficiencies, she is unsure if this shedding is normal and seeks advice.

A user is seeking hair loss treatments without using systemic DHT blockers like finasteride due to side effects. Suggestions include clascoterone (not FDA approved), pyrilutamide, RU58841, and low-dose topical finasteride, with a recommendation to consult a doctor.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

The user saw some improvement with topical minoxidil over 6-7 months and recently switched to oral minoxidil and finasteride, experiencing mild side effects from finasteride. They are concerned about losing gains from topical minoxidil and are seeking advice on whether to continue with the new regimen.

OP plans to switch from topical to oral minoxidil due to limited results and is advised to overlap both for a few weeks before discontinuing the topical. Oral minoxidil may be more effective for non-responders to topical treatment.

The user is seeking an alternative solvent for pyrilutamide due to skin irritation from ethanol and propylene glycol. They experienced similar issues with topical minoxidil.

The conversation discusses how applying topical tretinoin for 5 days can convert 43% of individuals who initially do not respond to minoxidil into responders, enhancing the effect of minoxidil on hair growth. Specific treatments mentioned are minoxidil and tretinoin.

A 20-year-old with a family history of male pattern baldness is seeking advice on using finasteride due to an allergy to minoxidil. They are considering whether to use topical or oral finasteride and what dosage to take.

Pyrilutamide, a potentially effective hair loss treatment; other topical treatments like RU58841 and CB-03-01 that may have fewer side effects than Pyrilutamide; and the Phase 3 clinical trials of Pyrilutamide, which is likely to be approved by the FDA soon.

A 25-year-old male has been using finasteride for 17 months and recently switched to dutasteride. His bloodwork shows increased luteinizing hormone levels, possibly due to increased testosterone, with no side effects and improved libido.

Users discuss their experiences with finasteride, expressing regret over delayed use due to misinformation and sharing mixed outcomes, including side effects and benefits. Treatments mentioned include finasteride, dutasteride, and minoxidil.

The experiences of users who have used RU58841 to treat hair loss, including both positive and negative effects. Some side effects reported include chest pain, joint pain in the hands, tinnitus, and increased heartbeat.

The conversation discusses hair loss and bloodwork results, focusing on zinc, vitamin D, and ferritin levels. The user is experiencing telogen effluvium after surgery and seeks advice on supplementation.

High DHEA levels may contribute to hair loss by increasing DHT in hair follicles, potentially explaining why finasteride is ineffective for some. Treatments like high-dose dutasteride and RU58841 are suggested, but the underlying cause, such as adrenal issues, should be investigated.

The conversation discusses alternative and unorthodox hair loss treatments, including RU58841, nandrolone, and dianabol, as well as theoretical approaches involving high doses of estrogen and selective estrogen receptor modulators. These methods are considered extreme and potentially harmful but are explored for those unable to tolerate traditional 5-alpha reductase inhibitors.

The conversation discusses the effectiveness of a hair loss treatment called CB (Breezula) in comparison to Pyrilutamide, and its potential when combined with Finasteride. There is uncertainty about when or if phase 3 trials for Breezula will begin.